Tolerance of MRSA ST239-TW to chlorhexidine-based decolonization: Evidence for keratinocyte invasion as a mechanism of biocide evasion.


Journal

The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424

Informations de publication

Date de publication:
02 2019
Historique:
received: 15 07 2018
revised: 30 09 2018
accepted: 20 10 2018
pubmed: 28 10 2018
medline: 29 5 2020
entrez: 28 10 2018
Statut: ppublish

Résumé

Information on genetic determinants of chlorhexidine tolerance (qacA carriage and MIC) in vitro is available, although evidence of the clinical impact and mechanisms remain poorly understood. We investigated why, following chlorhexidine intervention, prevalent epidemic MRSA ST22 and ST36 clones declined at an ICU, whilst an ST239-TW clone did not. The chlorhexidine tolerant ST239-TW phenotypes were assessed for their protein binding, cell adhesion and intracellular uptake potential. Six ST22, ST36 and ST239-TW bloodstream infection isolates with comparable chlorhexidine MICs were selected from a 2-year outbreak in an ICU at Guy's and St. Thomas' Hospital. Isolates were tested for fibrinogen and fibronectin binding, and adhesion/internalization into human keratinocytes with and without biocide. Binding to fibrinogen and fibronectin, adhesion and intracellular uptake within keratinocytes (P < 0.001) and intracellular survival in keratinocytes under chlorhexidine pressure (ST22 3.18%, ST36 4.57% vs ST239-TW 12.79%; P < 0.0001) was consistently higher for ST239-TW. We present evidence that MRSA clones with similarly low in vitro tolerance to chlorhexidine exhibit different in vivo susceptibilities. The phenomenon of S. aureus adhesion and intracellular uptake into keratinocytes could therefore be regarded as an additional mechanism of chlorhexidine tolerance, enabling MRSA to evade infection control measures.

Identifiants

pubmed: 30367885
pii: S0163-4453(18)30312-8
doi: 10.1016/j.jinf.2018.10.007
pii:
doi:

Substances chimiques

Disinfectants 0
Fibronectins 0
Fibrinogen 9001-32-5
Chlorhexidine R4KO0DY52L

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

119-126

Subventions

Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

Copyright © 2018 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Auteurs

Helene Marbach (H)

Faculty of Life Sciences and Medicine, Institute of Pharmaceutical Science, King's College London, UK.

Gema Vizcay-Barrena (G)

Centre for Ultrastructural Imaging, King's College London, Guy's Campus, London, UK.

Kaveh Memarzadeh (K)

Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Jonathan A Otter (JA)

Department of Infectious Diseases, Centre for Clinical Infection and Diagnostics Research (CIDR), King's College London & Guy's and St. Thomas' NHS Foundation Trust (GSTT), London, UK.

Smriti Pathak (S)

Department of Infectious Diseases, Centre for Clinical Infection and Diagnostics Research (CIDR), King's College London & Guy's and St. Thomas' NHS Foundation Trust (GSTT), London, UK.

Robert P Allaker (RP)

Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Richard D Harvey (RD)

Faculty of Life Sciences and Medicine, Institute of Pharmaceutical Science, King's College London, UK. Electronic address: richard.harvey@pharmazie.uni-halle.de.

Jonathan D Edgeworth (JD)

Department of Infectious Diseases, Centre for Clinical Infection and Diagnostics Research (CIDR), King's College London & Guy's and St. Thomas' NHS Foundation Trust (GSTT), London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH